Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE For validation, we directed expression of NPM-ALK, the fusion oncogene driving a subset of anaplastic large cell lymphoma (ALCL), to T-cells by infecting hematopoietic stem cells from Lck-Cre-transgenic mice with a retroviral construct containing the NPM-ALK cDNA preceded by a translational stop cassette. 31754210 2020
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Here, we report, a patient with no prior implant history who developed ALK (-) ALCL within the burn cicatrix of a breast. 31495882 2020
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 GeneticVariation disease BEFREE Breast implant-associated ALCL presents as a seroma with a median of 8-10 years after implant placement, lacks the ALK gene translocation and has an overall favourable but variable prognosis, depending on extent of disease at diagnosis and treatment. 31706671 2020
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL. 31804622 2020
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Overall survival was not different between patients with PD-L1+ vs PD-L1- anaplastic large cell lymphoma (p = 0.44), regardless of ALK status and International Prognostic Index (IPI) score. 31383967 2020
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30<sup>+</sup>/ALK<sup>+</sup> anaplastic large cell lymphoma (ALCL). 30742941 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Herein, we describe a well-characterized case of ALK-negative ALCL with no rearrangement but amplification of DUSP22/IRF4, diagnosed by cytologic examination of the pleural effusion in a 68-year-old white man with a 3-year history of unexplained eosinophilia and pulmonary infiltrates. 30016448 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Taken together, the novel ALK inhibitor ZYY has tremendous potential for treating human ALCL, and a combination of autophagy and ALK inhibition could effectively elicit potent antitumor effects. 31618659 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis. 30909793 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Immunohistochemistry was positive for CD30/CD4 and negative for anaplastic lymphoma kinase, confirming the presence of ALCL, then associated with gluteal implant, an event not described in literature. 31461013 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-ALK<sup>+</sup>) anaplastic large-cell lymphoma (ALCL) as model system, we found in cells and patient-derived tumor xenografts that STAT3 is constitutively acetylated as a result of ALK activity. 30692217 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE ALK is a receptor tyrosine kinase, associated with many tumor types as diverse as anaplastic large cell lymphomas, inflammatory myofibroblastic tumors, breast and renal cell carcinomas, non-small cell lung cancer, neuroblastomas, and more. 30813562 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Together, our findings suggest that CDK6 could be a therapeutic target for the development of future treatments for NPM-ALK<sup>+</sup> anaplastic large-cell lymphoma. 30262555 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomas are tumors that carry translocations involving the <i>ALK</i> gene at the 2p23 locus, leading to the expression of ALK tyrosine kinase fusion oncoproteins. 30679328 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas. 31419130 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 GeneticVariation disease BEFREE Methotrexate significantly induced apoptosis in ALK inhibitor-resistant cells expressing the NPM-ALK mutant harboring the point mutation, G262R, and in ALCL patient-derived NPM-ALK-positive Ki-JK cells. 31654627 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 GeneticVariation disease BEFREE TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating the anaplastic lymphoma kinase (ALK). 30131584 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Anaplastic large cell lymphoma (ALCL) is a type of T-cell lymphoma that can be divided into two categories: anaplastic lymphoma kinase-positive (ALK+) and ALK-negative.Gastrointestinal ALK+ ALCL is rare. 31423437 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL. 31705818 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE To determine how cancers acquire resistance to ALK inhibitors, we established a model of acquired crizotinib resistance by exposing a highly sensitive NPM-ALK-positive ALCL cell line to increasing doses of crizotinib until resistance emerged. 31177400 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Additional sequencing for a total of 238 T-NHLs confirmed the specificity of <i>MSC</i><sup>E116K</sup> for ALK<sup>-</sup> ALCL and further demonstrated that 14 of 15 mutated cases (93%) had coexisting <i>DUSP22</i> rearrangements. 31101622 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE The current World Health Organization classification system divides ALCLs into anaplastic lymphoma kinase (ALK)-positive and ALK-negative groups. 31667195 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE Genomic characterization performed in BIA-ALCL to date has demonstrated qualitatively similar molecular abnormalities to those seen in its more common counterpart [ALK-negative systemic anaplastic large cell lymphoma (sALCL)] including JAK/STAT activation and MYC/TP53 dysregulation. 30817557 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 Biomarker disease BEFREE A lymph node and bone marrow biopsy eventually revealed the presence of anaplastic lymphoma kinase+anaplastic large cell lymphoma. 30830032 2019
Ki-1+ Anaplastic Large Cell Lymphoma
0.600 AlteredExpression disease BEFREE CD99 expression was more frequent in ALK-positive ALCL but had no prognostic significance. 31078446 2019